REGULUS THERAPEUTICS INC (RGLS) Stock Price & Overview
NASDAQ:RGLS • US75915K3095
Current stock price
The current stock price of RGLS is 8.16 USD. Today RGLS is up by 0.25%. In the past month the price increased by 3.42%. In the past year, price increased by 357.14%.
RGLS Key Statistics
- Market Cap
- 564.917M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.73
- Dividend Yield
- N/A
RGLS Stock Performance
RGLS Stock Chart
RGLS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RGLS. When comparing the yearly performance of all stocks, RGLS is one of the better performing stocks in the market, outperforming 99.47% of all stocks.
RGLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RGLS. While RGLS has a great health rating, there are worries on its profitability.
RGLS Earnings
RGLS Forecast & Estimates
12 analysts have analysed RGLS and the average price target is 8.67 USD. This implies a price increase of 6.25% is expected in the next year compared to the current price of 8.16.
RGLS Groups
Sector & Classification
RGLS Financial Highlights
Over the last trailing twelve months RGLS reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.51% | ||
| ROE | -68.85% | ||
| Debt/Equity | 0 |
RGLS Ownership
RGLS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.95 | 364.65B | ||
| AMGN | AMGEN INC | 15.36 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.88 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.64 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.82 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.69 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.39 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.59 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.29 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RGLS
Company Profile
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The company went IPO on 2012-10-04. The firm is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The firm is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Company Info
IPO: 2012-10-04
REGULUS THERAPEUTICS INC
4224 Campus Point Court, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Joseph P. Hagan
Employees: 34
Phone: 18582026300
REGULUS THERAPEUTICS INC / RGLS FAQ
Can you describe the business of REGULUS THERAPEUTICS INC?
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The company went IPO on 2012-10-04. The firm is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The firm is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
What is the current price of RGLS stock?
The current stock price of RGLS is 8.16 USD. The price increased by 0.25% in the last trading session.
Does REGULUS THERAPEUTICS INC pay dividends?
RGLS does not pay a dividend.
What is the ChartMill rating of REGULUS THERAPEUTICS INC stock?
RGLS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about REGULUS THERAPEUTICS INC (RGLS) stock?
12 analysts have analysed RGLS and the average price target is 8.67 USD. This implies a price increase of 6.25% is expected in the next year compared to the current price of 8.16.
What is the ownership structure of REGULUS THERAPEUTICS INC (RGLS)?
You can find the ownership structure of REGULUS THERAPEUTICS INC (RGLS) on the Ownership tab.